News Archives - T2 Biosystems

How T2 Biosystems Inc. is utilizing miniaturized magnetic resonance technology for Lyme Disease

Rapid Diagnostic Tests and Their Effect on Antimicrobial Stewardship

T2 Biosystems Readies Biothreat Panel for FDA Submission While Keeping Eye on Sepsis Market

Increasing HAIs due to COVID-19 Stress the Need for a New Approach to Sepsis Diagnostics

HHS, Cohen Foundation Award $1M to Lyme Disease Dx Research Projects

T2 Biosystems awarded 100K for Lyme panel from HHS, Steven & Alexandra Cohen Foundation

Real-World Reports About Rapid Diagnostic Testing

T2 Biosystems inks distribution agreement in Baltic region

FDA grants breakthrough device designation for T2 Biosystems’ T2Lyme Panel

With FDA Filing, Lexington Firm Targets a Scourge of Hospitals: Sepsis

Panel Demonstrates Detection of Six Clinically Relevant Bacteria Species Directly from Whole Blood

FDA Allows Marketing of First Test for Yeast Pathogens

T2 BIOSYSTEMS OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.

JOIN IN ON TWITTER

T2 Biosystems

@T2Bio

Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.

March 31, 2023

T2 Biosystems

@T2Bio

Given the high attributable mortality and challenges with conventional diagnostic methods, the need for improved #rapiddiagnostics for #Candida species is evident. #whitepaper #diagnostics #fungi #fungalinfection #sepsis

March 30, 2023

SITEMAP

FOLLOW US ON SOCIAL

Please tell us where you are visiting from: United States | Outside the United States